Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio Pharmaceuticals has treated first patient in a Phase 1b placebo-controlled Ampion-In -Knee (AIK) trial of Ampion in Australia.
Subscribe to our email newsletter
The company expects to diagnose patients with a medical condition -pain and inflammation of the knee-osteoarthritis.
In this study, Ampion is injected into the knees of patients with osteoarthritis of the knee in combination with standard therapy, including steroids, aiming to demonstrate a reduction in pain and improved range of motion compared to placebo.
The study drug is planned to alleviate and confirm the hypothesis that the current outcome benefit is compatible with the mechanism of action of the drug.